Literature DB >> 27458220

In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Robert K Flamm1, Paul R Rhomberg2, Michael D Huband2, David J Farrell2.   

Abstract

Delafloxacin, an investigational anionic fluoroquinolone, is active against a broad range of Gram-positive and Gram-negative bacteria. In this study, 200 Streptococcus pneumoniae (plus 30 levofloxacin-resistant isolates), 200 Haemophilus influenzae, and 100 Moraxella catarrhalis isolates selected primarily from the United States (2014) were tested against delafloxacin and comparator agents. Delafloxacin was the most potent agent tested. MIC50 and MIC90 values against all S. pneumoniae isolates were 0.008 and 0.015 μg/ml. Delafloxacin susceptibility was not affected by β-lactamase status against H. influenzae and M. catarrhalis.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27458220      PMCID: PMC5038254          DOI: 10.1128/AAC.00941-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae.

Authors:  Margaret R Hammerschlag; Patricia M Roblin
Journal:  J Antimicrob Chemother       Date:  2004-06-09       Impact factor: 5.790

2.  In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.

Authors:  Laurel S Almer; Jennifer B Hoffrage; Erika L Keller; Robert K Flamm; Virginia D Shortridge
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

3.  Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus.

Authors:  Sandrine Lemaire; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

4.  In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

5.  In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.

Authors:  Angela M Nilius; Linus L Shen; Dena Hensey-Rudloff; Laurel S Almer; Jill M Beyer; Darlene J Balli; Yingna Cai; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

6.  Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.

Authors:  S J Harnett; A P Fraise; J M Andrews; G Jevons; N P Brenwald; R Wise
Journal:  J Antimicrob Chemother       Date:  2004-03-31       Impact factor: 5.790

7.  Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

8.  Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.

Authors:  George G Zhanel; Lorraine Palatnick; Kimberly A Nichol; Tracy Bellyou; Don E Low; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

9.  Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.

Authors:  George G Zhanel; Lorraine Palatnick; Kimberly A Nichol; Don E Low; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

  9 in total
  12 in total

1.  Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection Model.

Authors:  Olanrewaju O Okusanya; Alan Forrest; Sujata M Bhavnani; Prabhavathi Fernandes; Paul G Ambrose; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  BaxdelaTM (Delafloxacin): A Novel Fluoroquinolone for the Treatment of Acute Bacterial Skin and Skin Structure Infections.

Authors:  Alexandra Adler; Saira Chaudhry; Tamara Goldberg
Journal:  P T       Date:  2018-11

Review 3.  Underscoring interstrain variability and the impact of growth conditions on associated antimicrobial susceptibilities in preclinical testing of novel antimicrobial drugs.

Authors:  David A Sanchez; Luis R Martinez
Journal:  Crit Rev Microbiol       Date:  2018-12-06       Impact factor: 7.624

Review 4.  Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin.

Authors:  Jennifer Shiu; Grace Ting; Tony Kl Kiang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-06       Impact factor: 2.441

5.  In Vivo Pharmacodynamic Target Determination for Delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the Neutropenic Murine Pneumonia Model.

Authors:  Miao Zhao; Alexander J Lepak; Karen Marchillo; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

Review 6.  Potential new fluoroquinolone treatments for suspected bacterial keratitis.

Authors:  Rose Herbert; Mary Caddick; Tobi Somerville; Keri McLean; Shakeel Herwitker; Timothy Neal; Gabriela Czanner; Stephen Tuft; Stephen B Kaye
Journal:  BMJ Open Ophthalmol       Date:  2022-07

Review 7.  Clinical Utility of Lefamulin: If Not Now, When?

Authors:  Nicholas J Mercuro; Michael P Veve
Journal:  Curr Infect Dis Rep       Date:  2020-07-09       Impact factor: 3.725

8.  In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014.

Authors:  M A Pfaller; H S Sader; P R Rhomberg; R K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

9.  Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone.

Authors:  M A Pfaller; R K Flamm; S P McCurdy; C M Pillar; D Shortridge; R N Jones
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948

Review 10.  Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties.

Authors:  Sarah C J Jorgensen; Nicholas J Mercuro; Susan L Davis; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2018-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.